Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 20;11(9):e0163254.
doi: 10.1371/journal.pone.0163254. eCollection 2016.

Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series

Min-Young Lee  1 , Won Jin Chang  1 , Hae Su Kim  1 , Ji Yun Lee  1 , Sung Hee Lim  1 , Jeong Eon Lee  2 , Seok Won Kim  2 , Seok Jin Nam  2 , Jin Seok Ahn  1 , Young-Hyuck Im  1 , Yeon Hee Park  1
Affiliations

Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series

Min-Young Lee et al. PLoS One. .

Abstract

Purpose: The purpose of this study was to investigate the clinicopathologic features and prognostic factors affecting outcome in patients with isolated locoregional recurrence of breast cancer (ILRR).

Methods: We retrospectively analyzed the medical records of 104 patients who were diagnosed with ILRR and underwent curative surgery from January 2000 to December 2010 at Samsung Medical Center.

Results: Among 104 patients, 43 (41%) underwent total mastectomy and 61 (59%) underwent breast-conserving surgery for primary breast cancer. The median time from initial operation to ILRR was 35.7 months (4.5-132.3 months). After diagnosis of ILRR, 45 (43%) patients were treated with mastectomy, 41 (39%) with excision of recurred lesion, and 18 (17%) with node dissection. During a median follow-up of 8.9 years, the 5-year overall survival was 77% and 5-year distant metastasis-free survival (DMFS) was 54%. On multivariate analysis, younger age (< 35 years), higher stage, early onset of elapse (≤ 24 months), lymph node recurrences, and subtype of triple negative breast cancer (TNBC) were found to be independently associated with DMFS. Patients in the no chemotherapy group showed a longer DMFS after surgery for ILRR than those treated with chemotherapy (median 101.5 vs. 48.0 months, p = 0.072) but without statistical significance.

Conclusion: Our analysis showed that younger age (< 35 years), higher stage, early onset of relapse (≤ 24 months), lymph node recurrence, and subtype of TNBC are the worst prognostic factors for ILRR.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient cohort.
SMC, Samsung Medical Center; LN, lymph node.
Fig 2
Fig 2. Kaplan-Meier curves: Distant metastasis-free (A) and overall (B) survival by the stage.
ILRR, isolated locoregional recurrence.
Fig 3
Fig 3. Kaplan-Meier curves: Distant metastasis-free (A) and overall (B) survival by tumor subtype.
ILRR, isolated locoregional recurrence; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, Triple negative breast cancer.
See this image and copyright information in PMC

References

    1. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 2000;355: 1757–1770. - PubMed
    1. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27: 2466–2473. 10.1200/JCO.2008.19.8424 - DOI - PMC - PubMed
    1. Clemons M, Danson S, Hamilton T, Goss P. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev. 2001;27: 67–82. - PubMed
    1. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21: 293–298. - PubMed
    1. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, et al. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27–02, BIG 1–02, and NSABP B-37. Clin Breast Cancer. 2008;8: 287–292. 10.3816/CBC.2008.n.035 - DOI - PubMed